Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Market Leaders Maintain Their Upper Hand

Executive Summary

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts. 

You may also be interested in...



GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer

The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.

Sanofi Myeloma Drug Shines But Darzalex Dominates Still

While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.

Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space

Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel